ZA201101160B - Benzoimidazole derivatives and glycogen synthase kinse-3 beta inhibitors containing the same - Google Patents

Benzoimidazole derivatives and glycogen synthase kinse-3 beta inhibitors containing the same

Info

Publication number
ZA201101160B
ZA201101160B ZA2011/01160A ZA201101160A ZA201101160B ZA 201101160 B ZA201101160 B ZA 201101160B ZA 2011/01160 A ZA2011/01160 A ZA 2011/01160A ZA 201101160 A ZA201101160 A ZA 201101160A ZA 201101160 B ZA201101160 B ZA 201101160B
Authority
ZA
South Africa
Prior art keywords
kinse
same
glycogen synthase
inhibitors containing
beta inhibitors
Prior art date
Application number
ZA2011/01160A
Other languages
English (en)
Inventor
Mitsuaki Ohtani
Yo Matsuo
Yingfu Li
Joel R Walker
David M Jenkins
Feryan Ahmed
Ryuji Ohsawa
Shoji Hisada
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of ZA201101160B publication Critical patent/ZA201101160B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA2011/01160A 2008-07-30 2011-02-14 Benzoimidazole derivatives and glycogen synthase kinse-3 beta inhibitors containing the same ZA201101160B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8477008P 2008-07-30 2008-07-30
PCT/US2009/052225 WO2010014794A1 (en) 2008-07-30 2009-07-30 Benzoimidazole derivatives and glycogen synthase kinase-3 beta inhibitors containing the same

Publications (1)

Publication Number Publication Date
ZA201101160B true ZA201101160B (en) 2011-10-26

Family

ID=41610727

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2011/01160A ZA201101160B (en) 2008-07-30 2011-02-14 Benzoimidazole derivatives and glycogen synthase kinse-3 beta inhibitors containing the same

Country Status (14)

Country Link
US (1) US20110190351A1 (enExample)
EP (1) EP2309855A4 (enExample)
JP (1) JP2011529903A (enExample)
KR (1) KR20110040958A (enExample)
CN (1) CN102170785A (enExample)
AU (1) AU2009276548A1 (enExample)
BR (1) BRPI0916726A2 (enExample)
CA (1) CA2732280A1 (enExample)
CO (1) CO6351688A2 (enExample)
IL (1) IL210863A0 (enExample)
MX (1) MX2011001170A (enExample)
RU (1) RU2011107227A (enExample)
WO (1) WO2010014794A1 (enExample)
ZA (1) ZA201101160B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8362268B2 (en) 2008-05-30 2013-01-29 University Of Notre Dame Du Lac Anti-bacterial agents from benzo[d]heterocyclic scaffolds for prevention and treatment of multidrug resistant bacteria
CN101619058A (zh) * 2009-01-08 2010-01-06 上海交通大学 一种苯并咪唑-4-酰胺型衍生物
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US9815787B2 (en) * 2013-12-12 2017-11-14 University Of Tsukuba Sulfonamide derivative or pharmaceutically acceptable acid addition salt thereof
CN105461722B (zh) * 2014-09-04 2019-05-10 欣凯医药化工中间体（上海）有限公司 一种脱氮嘌呤类化合物及其衍生物及其制备方法和应用
WO2016133160A1 (ja) * 2015-02-19 2016-08-25 国立大学法人筑波大学 スルホンアミド誘導体またはその薬学的に許容される酸付加塩
US20240132485A1 (en) * 2020-10-16 2024-04-25 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof
KR20240008807A (ko) * 2022-07-12 2024-01-19 주식회사 넥스트젠바이오사이언스 Hif-1 단백질 억제제로서의 신규한 퓨린 유도체 화합물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0178413A1 (en) * 1984-08-17 1986-04-23 Beecham Group Plc Benzimidazoles
FR2699816B1 (fr) * 1992-12-30 1995-03-03 Oreal Compositions tinctoriales pour fibres kératiniques à base de paraphénylènediamines, de métaphénylènediamines et de dérivés du benzimidazole, et procédé de teinture les mettant en Óoeuvre.
US7064215B2 (en) * 2001-07-03 2006-06-20 Chiron Corporation Indazole benzimidazole compounds
RU2004126671A (ru) * 2002-02-06 2005-04-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) Гетероарилсоединения, полезные в качестве ингибиторов gsk-3
JP2006515013A (ja) * 2003-01-23 2006-05-18 クリスタルジェノミクス、インコーポレイテッド グリコーゲン合成酵素キナーゼ３β活性抑制剤、組成物及びその製造方法
AU2009310310A1 (en) * 2008-10-30 2010-05-06 Oncotherapy Science, Inc. 7-Hydroxy-benzoimidazole-4-yl-methanone Derivatives and PBK inhibitors containing the same
EP2358365A4 (en) * 2008-11-20 2012-05-30 Oncotherapy Science Inc GLYCOGEN SYNTHASE KINASE 3 BETA HEMMER WITH 7-HYDROXY BENZOIMIDAZOLE-4-YL METHANONE DERIVATIVES

Also Published As

Publication number Publication date
CO6351688A2 (es) 2011-12-20
EP2309855A1 (en) 2011-04-20
CA2732280A1 (en) 2010-02-04
WO2010014794A1 (en) 2010-02-04
RU2011107227A (ru) 2012-09-10
US20110190351A1 (en) 2011-08-04
BRPI0916726A2 (pt) 2017-07-04
EP2309855A4 (en) 2012-06-27
KR20110040958A (ko) 2011-04-20
JP2011529903A (ja) 2011-12-15
MX2011001170A (es) 2011-04-05
CN102170785A (zh) 2011-08-31
AU2009276548A1 (en) 2010-02-04
IL210863A0 (en) 2011-04-28

Similar Documents

Publication Publication Date Title
IL210863A0 (en) Benzoimidazole derivatives and glycogen synthase kinase-3 beta inhibitors containing the same
IL284889A (en) Imidazotriazines and imidazopyrimidines as kinase inhibitors
IL219646A0 (en) Novelnaphthyridine derivatives and the use thereof as kinase inhibitors
ZA201101586B (en) Aminotriazolopyridines and their use as kinase inhibitors
IL211042A0 (en) Imidazopyridin-2-one derivatives and uses thereof
ZA201103635B (en) Azaquinolinone derivatives and uses thereof
IL210412A0 (en) Heterocyclic derivatives and uses thereof
ZA201009073B (en) Heterocyclic compound and use thereof
IL213000A0 (en) Raf inhibitors and their uses
IL201379A0 (en) Inhibitors iap
ZA200906118B (en) Descenting systems and methods
EP2200977A4 (en) F1F0-ATPASE INHIBITOR AND ASSOCIATED METHODS
GB0803559D0 (en) Multiple path intererometer and method
IL205571A0 (en) 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin
EP2240029A4 (en) COMPOUNDS FOR USE AGAINST INFLAMMATORY AND IMMUNOMIC DISEASES
EP2184994A4 (en) HETEROCYCLIC ARYL COMPOUNDS FOR INFLAMMATORY CONDITIONS AND IMMUNE DISORDERS
IL212755A0 (en) Pyrazinopyrazines and derivatives as kinase inhibitors
EP2335213A4 (en) SYSTEMS AND METHODS FOR TRANSFERRING VALUE
EP2182808A4 (en) Pyridine compounds for inflammatory and immune uses
ZA201001300B (en) Antigen-asjuvant compositions and methods
PL3326794T3 (pl) Urządzenie do transportu i składania wykrojów
ZA201103964B (en) 7-hydroxy-benzoimidazole-4-yl-methanone derivatives and pbk inhibitors containing the same
IL208771A0 (en) Iminopyridine derivatives and use thereof
IL213321A0 (en) Descenting systems and methods
GB0918601D0 (en) Decahydro-1H-Indenoquinolinone and decahydro-3H-cyclopenaphenanthridinone CYP17 inhibitors